Approach to Altered PT, aPTT, and INR

Understanding What Each Test Measures

The INR = (PT / PT normal mean)^ISI. It was developed to standardize vitamin K antagonist monitoring and is used in liver disease assessment, though it may overestimate bleeding risk in mild liver dysfunction. PT reagents have variable sensitivity to direct Xa inhibitors; PT is usually normal with apixaban.

• Harrison's Principles of Internal Medicine 22E, p. 518

Step 1 - Pre-Analytical Checks Before Interpreting Results

• Underfilled tube (must be >90% fill) - gives falsely prolonged PT/aPTT
• High hematocrit (>55%) - decreases plasma:anticoagulant ratio, gives false values
• Poor mixing or delayed processing

• Harrison's Principles of Internal Medicine 22E, p. 518

Step 2 - Pattern Recognition (The Core Framework)

Pattern 1: Isolated Prolonged PT (aPTT normal)

Pattern 2: Isolated Prolonged aPTT (PT normal)

• Harrison's Principles of Internal Medicine 22E, Table 69-3

Pattern 3: Both PT and aPTT Prolonged

• Fibrinogen deficiency: TT ↑↑, aPTT ↑↑, PT ↑↑
• Prothrombin (FII) or FV deficiency: TT normal, aPTT ↑, PT ↑
• Factor X deficiency: TT normal, aPTT ↑, PT ↑
• Vitamin K-dependent factor deficiency: TT normal, aPTT ↑, PT ↑↑
• Goldman-Cecil Medicine, Table 157-2

Step 3 - The Mixing Study (Distinguishing Factor Deficiency vs. Inhibitor)

Corrects immediately AND stays corrected on incubation at 37°C
→ FACTOR DEFICIENCY (normal plasma supplied the missing factor)

Corrects immediately but PROLONGS on incubation at 37°C
→ ACQUIRED FACTOR INHIBITOR (most commonly acquired factor VIII inhibitor)

Does NOT correct at any time point
→ INHIBITOR present (lupus anticoagulant, heparin, paraproteins, fibrin split products)

• Harrison's Principles of Internal Medicine 22E, p. 518

Step 4 - Specific Second-Line Tests

Step 5 - Clinical Context Integration

• Liver disease: PT/INR prolonged earliest (factor VII), then aPTT; thrombocytopenia often co-exists. Note: mild INR elevation may overestimate true bleeding risk (thrombin generation may be preserved).
• DIC: PT ↑ + aPTT ↑ + platelets ↓ + fibrinogen ↓ + D-dimer ↑ - treat the underlying cause.
• Warfarin: Isolated PT/INR prolongation; aPTT can also prolong at supratherapeutic levels.
• Heparin (UFH): Predominantly prolongs aPTT; TT also prolonged; reptilase time normal.
• Dabigatran: Prolongs TT markedly; aPTT sensitive but not linear.
• Apixaban: PT often normal; anti-Xa assay needed to assess drug levels.
• Hemophilia A/B: Isolated aPTT prolongation, corrects on mixing, factor VIII or IX assay confirms.
• Lupus anticoagulant: aPTT prolonged, does NOT correct on mixing, dRVVT confirmatory, associated with thrombosis not bleeding.

Quick Algorithm Summary

ABNORMAL PT / aPTT / INR
         ↓
1. Exclude pre-analytical error (repeat if needed)
         ↓
2. Pattern:
   PT only ↑ → Extrinsic (FVII, early VitK deficiency, warfarin, Xa inhibitors)
   aPTT only ↑ → Intrinsic (FVIII/IX/XI deficiency, heparin, lupus AC, XII/HMWK/PK)
   Both ↑ → Common pathway / multiple (liver disease, DIC, VitK deficiency, FV/FX/FII/Fibrinogen)
         ↓
3. Mixing study (1:1 patient:normal plasma):
   Corrects → Factor deficiency → specific factor assay
   No correction → Inhibitor → lupus AC workup (dRVVT), factor inhibitor assay
         ↓
4. Correlate with: clinical bleeding, family history, medications, liver function, DIC screen

• Orange (left) - Isolated PT elevation - points to extrinsic pathway problems (Factor VII, early vitamin K deficiency, warfarin, rivaroxaban)
• Red (center) - Both PT and aPTT elevated - common/multiple pathway involvement (DIC, liver disease, severe vitamin K deficiency, supratherapeutic heparin)
• Blue (right) - Isolated aPTT elevation - intrinsic pathway, leads to the mixing study

• Corrects (green) - factor deficiency - proceed to specific factor assays
• No correction (purple) - inhibitor present
  • Immediate non-correction - Lupus Anticoagulant (confirm with dRVVT; causes thrombosis, not bleeding)
  • Corrects then prolongs on 37°C incubation - Acquired Factor VIII inhibitor

Recent Guidelines on Perioperative Coagulation Management (2024-2026)

1. ISTH SSC - Surgical & Procedural Bleed Risk Stratification (2026)

• Provides a practical procedure-specific bleeding risk stratification framework for use in adults on anticoagulation undergoing elective procedures
• Addresses when to interrupt anticoagulation, for how long, and when to safely restart
• Recognizes that discordant perioperative management is largely driven by the lack of harmonized bleed risk schemas
• Intended to work alongside thromboembolic risk assessment tools

2. ISTH SSC - Reversal of Direct Oral Anticoagulants (2024)

• Also covers reversal of oral FXIa inhibitors (a new class currently in clinical development)
• Non-specific agents (4-factor PCC, activated PCC) remain a fallback option when specific reversal agents are unavailable

3. 2025 DOAC Guidelines - Practical Perioperative & Bleeding Management

• No routine "bridging" with LMWH when interrupting DOACs for planned procedures - this is now firmly consensus across guidelines
• DOACs do not require routine laboratory testing for monitoring
• For planned procedures: interrupt and resume without bridging
• Coagulation test guidance for urgent surgery:
  • aPTT for dabigatran (qualitative guidance)
  • PT ratio for rivaroxaban (ratio ≤1.2 with high probability rules out significant activity)
  • PT is not reliable for apixaban or edoxaban - use anti-Xa assay
  • Plasma DOAC levels <30 ng/mL considered acceptable for surgery with standard bleeding risk

4. 2025 Multisociety Consensus - Perioperative Antithrombotic Management (Spain/Europe)

• For UFH: discontinue 4-6 hours before the procedure; 12 hours for prophylactic doses
• For VKAs (warfarin): restart as early as possible postoperatively (requires 36-48 hours to achieve therapeutic effect)
• When bridging is needed: restart heparin (LMWH or UFH) at therapeutic doses within the first 24 hours postoperatively
• Neuraxial/regional anesthesia with DOACs (per 2025 ASRA 5th edition guidelines):
  • High-dose DOACs: 72-hour hold before neuraxial procedures
  • Acceptable residual DOAC: levels <30 ng/mL or anti-Xa activity ≤0.1 IU/mL
  • Reversal agents (andexanet alfa, idarucizumab, PCC) are not recommended for routine reversal prior to neuraxial procedures

5. French National Authority for Health (HAS) - Perioperative Patient Blood Management (2024)

6. Perioperative Management of Antithrombotics in Intracranial Surgery (2024)

• Best methodological quality: European Society of Anaesthesiology (ESA) guidelines (two sets) and American College of Chest Physicians (ACCP)
• Highlights ongoing uncertainty due to lack of high-quality RCT data in neurosurgical patients specifically
• Key tension: risk of thromboembolism vs. perioperative hemorrhage in a closed intracranial space

7. HIT in Cardiac Surgery - ISTH Guidance (2026)

Summary of Cross-Guideline Consensus Points (2024-2026)

Factor XII / HMWK / Prekallikrein Deficiency - Clinical Approach

The Paradox in One Sentence

The Contact Activation System - What It Is

Negatively charged surface (glass, kaolin, celite, ellagic acid)
        ↓
FXII → FXIIa  [HMWK as cofactor]
        ↓
Prekallikrein → Kallikrein  [amplification loop back to FXII]
        ↓
FXI → FXIa → FIX → FX → Thrombin → Fibrin

• Goldman-Cecil Medicine, p. 1798 | Braunwald's Heart Disease, Chapter 95

Why the aPTT is Markedly Prolonged

A clue: an aPTT >100-120 seconds with completely no bleeding history strongly suggests a contact factor deficiency rather than hemophilia A or B.

Key Clinical Features - Comparison Table

Hageman (FXIIa) deficiency: the original patient after whom factor XII was named died of a pulmonary embolism - highlighting the paradox.

Diagnostic Approach

Step 1 - Recognize the Pattern

• Isolated markedly prolonged aPTT + PT normal + no bleeding history = contact factor deficiency until proven otherwise

Step 2 - Exclude Heparin Contamination

• Clinical history (heparin flushes in lines)
• Heparin neutralization (Hepzyme procedure)
• Thrombin time: prolonged in heparin; reptilase time: normal in heparin

Step 3 - Mixing Study (1:1 patient + normal plasma)

• Contact factor deficiency: corrects on mixing
• Rosner Index: (mix aPTT - normal aPTT) / patient aPTT × 100
  • <12% = correction (factor deficiency)
  • 12-15% = gray zone
  • >15% = no correction (inhibitor)

A Special Clue: Incubation Time Effect

• Kaolin/celite can slowly activate residual FXII even at low levels
• Prekallikrein deficiency in particular may "normalize" aPTT on longer incubation

If aPTT shortens or normalizes with prolonged incubation time → strongly suggests prekallikrein deficiency

• Goldman-Cecil Medicine, p. 2142 | Quick Compendium of Clinical Pathology 5th ed.

Step 4 - Specific Factor Assays

• Factor XII activity assay
• Prekallikrein (PK) activity assay
• HMWK activity assay
• These are available at specialized coagulation labs

Management

No treatment is required for contact activation factor deficiencies, regardless of how prolonged the aPTT is.

"Deficiencies of the contact activation factors, however severe they are and however prolonged the associated aPTT may be, do not cause clinical bleeding problems, even in response to surgery or trauma. Therefore, no therapy is indicated." - Goldman-Cecil Medicine, p. 2147

The Thrombosis Paradox - Emerging Biology

• Medical devices (stents, mechanical valves, CPB circuits, ECMO) activate FXII on foreign surfaces → device-related thrombosis
• Neutrophil extracellular traps (NETs) activate the contact pathway → thromboinflammation
• Polyphosphates released from platelet dense granules activate FXII in vivo
• Animal studies: FXII-deficient mice form small, unstable thrombi at sites of arterial/venous injury
• In humans: Factor XI antisense oligonucleotides and FXIa inhibitors reduce postoperative VTE better than enoxaparin in knee arthroplasty

• Braunwald's Heart Disease, Chapter 95 | Henry's Clinical Diagnosis and Management by Laboratory Methods

Quick Summary Algorithm

Markedly prolonged aPTT + PT normal + NO bleeding history
                    ↓
         Exclude heparin contamination
                    ↓
              Mixing study → Corrects
                    ↓
     Does aPTT normalize on prolonged incubation?
         YES → Prekallikrein deficiency likely
         NO  → Factor XII or HMWK deficiency likely
                    ↓
     Specific factor assays: FXII, PK, HMWK
                    ↓
     DIAGNOSIS CONFIRMED
     ↓                        ↓
NO TREATMENT NEEDED     Screen for VTE risk
Proceed with surgery    Standard anticoagulation if thrombosis